New cancer pill enters human testing for advanced tumors

NCT ID NCT07358806

Recruiting now Disease control Sponsor: Oscotec Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an experimental oral drug called OCT-598 in 51 adults with advanced solid tumors, including breast, lung, and prostate cancers. The study aims to find the safest dose and see if the drug works alone or with standard chemotherapy. It is too early to know if it will help patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCT-598 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors like breast, lung, or prostate cancer.
What could go wrong: This is a very early Phase 1 trial with only 51 participants, so safety and dosing are the main goals. It may not show strong anti-cancer effects, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm gastroesophageal cancer head and neck cancer Head and Neck Neoplasms neoplasm non-small cell lung carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER HEAD AND NECK CANCER NON-SMALL CELL LUNG CANCER PROSTATE CANCER SOLID TUMOR

Contacts and locations

Locations

Asan Medical Center
NOT_YET_RECRUITING

Seoul, South Korea
National Cancer Center
RECRUITING

Goyang-si, South Korea
Seoul National University Bundang Hospital (SNUBH)
RECRUITING

Seongnam-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.